Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas.
Glioblastoma
Gliomatosis cerebri growth patterns
Histologically lower-grade gliomas
IDH wild-type
The 2021 WHO classification
WHO grade 4
Journal
Brain tumor pathology
ISSN: 1861-387X
Titre abrégé: Brain Tumor Pathol
Pays: Japan
ID NLM: 9716507
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
29
01
2023
accepted:
18
03
2023
medline:
20
4
2023
pubmed:
30
3
2023
entrez:
29
3
2023
Statut:
ppublish
Résumé
The 2021 World Health Organization (WHO) classification of central nervous system tumors applied molecular criteria and further integrated histological and molecular diagnosis of gliomas. This classification allows for the diagnosis of isocitrate dehydrogenase wild-type (IDHwt) glioblastoma (GBM), and WHO grade 4 with histologically lower-grade gliomas (LrGGs), even in the absence of high-grade histopathologic features, such as necrosis and/or microvascular proliferation. They contain at least one of the following molecular features: epidermal growth factor receptor amplification, chromosome 7 gain/10 loss, or telomerase reverse transcriptase promoter mutation. In the imaging features at the time of histological diagnosis, a gliomatosis cerebri growth pattern was frequently observed in these tumors. Furthermore, this growth pattern was significantly higher in IDHwt GBM, WHO grade 4, with histological grade II gliomas. Although the exact prognosis of IDHwt GBM, WHO grade 4, with histologically LGGs remains unknown, its OS was approximately 1-2 years similar to that of histologically IDHwt GBM, WHO grade 4, despite histopathological features similar to IDHmut LrGGs. These findings reinforce the need for the analysis of molecular features, regardless of presenting similar clinical characteristics and imaging features to IDHmut LrGGs.
Identifiants
pubmed: 36988764
doi: 10.1007/s10014-023-00458-5
pii: 10.1007/s10014-023-00458-5
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
48-55Subventions
Organisme : Japan Society for the Promotion of Science
ID : 21K09174
Informations de copyright
© 2023. The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology.
Références
Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468
doi: 10.1038/ng.3273
pubmed: 25848751
Aoki K, Nakamura H, Suzuki H et al (2017) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. https://doi.org/10.1093/neuonc/nox132
doi: 10.1093/neuonc/nox132
pmcid: 5693126
Sanai N, Polley MY, McDermott MW et al (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:3–8
doi: 10.3171/2011.2.JNS10998
pubmed: 21417701
Brown TJ, Brennan MC, Li M et al (2016) Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol 2:1460–1469
doi: 10.1001/jamaoncol.2016.1373
pubmed: 27310651
pmcid: 6438173
Motomura K, Natsume A, Watanabe R et al (2012) Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci 103:1871–1879
doi: 10.1111/j.1349-7006.2012.02377.x
pubmed: 22747609
pmcid: 7659188
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820
doi: 10.1007/s00401-016-1545-1
pubmed: 27157931
Motomura K, Chalise L, Ohka F et al (2021) Impact of the extent of resection on the survival of patients with grade II and III gliomas using awake brain mapping. J Neurooncol 153:361–372
doi: 10.1007/s11060-021-03776-w
pubmed: 34009509
Motomura K, Natsume A, Iijima K et al (2017) Surgical benefits of combined awake craniotomy and intraoperative magnetic resonance imaging for gliomas associated with eloquent areas. J Neurosurg 127:790–797
doi: 10.3171/2016.9.JNS16152
pubmed: 28059650
Gerber NK, Goenka A, Turcan S et al (2014) Transcriptional diversity of long-term glioblastoma survivors. Neuro Oncol 16:1186–1195
doi: 10.1093/neuonc/nou043
pubmed: 24662514
pmcid: 4136896
Michaelsen SR, Urup T, Olsen LR et al (2018) Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival. J Neurooncol 137:533–542
doi: 10.1007/s11060-017-2739-7
pubmed: 29305787
Aoki K, Nakamura H, Suzuki H et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66–77
doi: 10.1093/neuonc/nox132
pubmed: 29016839
Stichel D, Ebrahimi A, Reuss D et al (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136:793–803
doi: 10.1007/s00401-018-1905-0
pubmed: 30187121
Metellus P, Coulibaly B, Colin C et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719–729
doi: 10.1007/s00401-010-0777-8
pubmed: 21080178
Brat DJ, Aldape K, Colman H et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol 136:805–810
doi: 10.1007/s00401-018-1913-0
pubmed: 30259105
pmcid: 6204285
Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Berzero G, Di Stefano AL, Ronchi S et al (2021) IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol 23:955–966
doi: 10.1093/neuonc/noaa258
pubmed: 33173941
Wijnenga MMJ, French PJ, Dubbink HJ et al (2018) The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol 20:103–112
doi: 10.1093/neuonc/nox176
pubmed: 29016833
Grogan D, Bray DP, Cosgrove M et al (2022) Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review. J Neurooncol 157:187–195
doi: 10.1007/s11060-022-03961-5
pubmed: 35212929
pmcid: 9703358
Aibaidula A, Chan AK, Shi Z et al (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 19:1327–1337
doi: 10.1093/neuonc/nox078
pubmed: 28575485
pmcid: 5596181
Tabouret E, Nguyen AT, Dehais C et al (2016) Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 132:625–634
doi: 10.1007/s00401-016-1611-8
pubmed: 27573687
Cancer genome atlas research N, Brat DJ, Verhaak RG et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498
doi: 10.1056/NEJMoa1402121
Tesileanu CMS, Dirven L, Wijnenga MMJ et al (2020) Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-now criteria. Neuro Oncol 22:515–523
doi: 10.1093/neuonc/noz200
pubmed: 31637414
Ding H, Huang Y, Li Z et al (2019) Prediction of IDH status through MRI features and enlightened reflection on the delineation of target volume in low-grade gliomas. Technol Cancer Res Treat 18:1533033819877167
doi: 10.1177/1533033819877167
pubmed: 31564237
pmcid: 6767744
Park YW, Han K, Ahn SS et al (2018) Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. AJNR Am J Neuroradiol 39:37–42
doi: 10.3174/ajnr.A5421
pubmed: 29122763
pmcid: 7410710
van Lent DI, van Baarsen KM, Snijders TJ et al (2020) Radiological differences between subtypes of WHO 2016 grade II-III gliomas: a systematic review and meta-analysis. Neurooncol Adv. https://doi.org/10.1093/noajnl/vdaa044
doi: 10.1093/noajnl/vdaa044
pubmed: 32642698
pmcid: 7236393
Kibe Y, Motomura K, Ohka F et al (2023) Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series. Sci Rep. https://doi.org/10.1038/s41598-022-25928-2
doi: 10.1038/s41598-022-25928-2
pubmed: 36646712
pmcid: 9842655